



There is a magic when medical and Al ethics are the best friends

MAPS Digital FAWG webinar 21 April 2021



The views expressed in this Webinar are those of the presenters, and are not an official position statement by MAPS, nor do they necessarily represent the views of the MAPS organization or its members.

This presentation is for informational purposes only and is not intended as legal or regulatory advice.

Housekeeping

Questions for Presenters:	Evaluations:	On-demand Availability of Webinar:
Please submit questions throughout the presentation using the Q&A button in your control panel.	The control panel includes a webinar ev aluation. Please complete that ev aluation so that we can work to ensure the highest quality presentations.	This webinar and corresponding PowerPoint deck, as with all previous ones will be av ailable next week or demand for members via the MAPS website content hub.

Presenters



Sameer Lal

SVP Business Development Indegene UK

MAPS Digital Strategy FAWG Co-Lead Moderator



Rahela Penovski

Pharmacist in industry UK



Matthew Michelson PhD

President, Genesis Al Genesis Research USA This session will provide a learning opportunity for our audience by:

- Opening the dialog on a controversial topic
- Providing some practical examples on the topic
- Unleashing opportunities for better understanding and collaboration between experts in AI and medical

- Do you personally consider the possibility of a resonance between AI ethics and medical ethics?
- 1. Yes, I do and I am actively looking to understand and exercise it
- 2. Yes, I do but am not clear on the specifics
- 3. Yes, I do but I am waiting on others to do something about it first
- 4. No, I do not see any connection whatsoever



Two best friends – medical and Al ethics – what, why and how

Rahela Penovski* Pharmacist in industry

*Conflict of Interest: The presentation is personal view of Rahela Penovski and part of her PhD work.

Medical Affairs Professional Society (MAPS) | 2021

Aim

- Warming up
 - What is medical ethics and why it is important
 - What is AI ethics and why it is important
- Starting race
 - Why medical and AI ethics should resonate with each other
- Winning
 - How to do it effectively

Medical Ethics

"The analytical activity in which the concepts, assumptions, beliefs, attitudes, emotions, reasons and arguments underlying medico-moral decision making are examined critically"




AI Ethics

"Al ethics is a set of values, principles, and techniques that employ widely accepted standards of right and wrong to guide moral conduct in the development and use of AI technologies"



Why resonance is needed?






Improvement in patient outcome




Medical Affairs Professional Society (MAPS) | 2021

Being effective – working smart instead of hard









How likely are you to be looking for any AI technology in the next year?

- 1. For sure (90-100% chances it is going to happen)
- 2. Highly likely (50-89% chances it is going to happen)
- 3. Possibly (20-49% chances it is going to happen)
- 4. Low priority (1-19% chances it is going to happen)
- 5. Not at all (no chance it is going to happen)



Applying the 5 tenets of Medical Ethics within the Evid Science platform: A Case Study

Matthew Michelson, PhD*

Genesis Research

*Conflict of Interest: Matthew Michelson is the President of Genesis AI, a division of Genesis Research that sells the Evid Science platform. The following talk is a case study from that platform.

Using AI to surface results from the literature

- Help me find the survival rates for patients with Non-Small Cell Lung Cancer and Cachexia
 - Time constraint due to in-licensing time pressures
 - Depth for landscape analysis in strategic decisions
 - Discover broader results than manual efforts

Tenet: Autonomy (human choice)

The machine never tells the human what to do!

- AI = data preparer
- Human = data user

From baseline to immediately prior to Cycle 2, 208 (32%) gained weight; 225 (34%) lost <2% of baseline weight; and 223 (34% of 656) lost 2% or more.

Result	Intervention	Outcome
208 of 650		From baseline to immediately prior to Cycle 2, gained weight
225 of 662		From baseline to immediately prior to Cycle 2, lost <2% of baseline weight
223 of 656		From baseline to immediately prior to Cycle 2, lost 2% or more

Median survival from the beginning of Cycle 2 was 13.0, 10.9, and 6.9 months for patients with weight gain, weight loss of <2%, and weight loss of 2% or more, respectively.

Result	Intervention	Outcome
13 months	patients with weight gain	Median survival from the beginning of Cycle 2
10.9 months	patients with, weight loss of <2%, weight loss of 2% or more	Median survival from the beginning of Cycle 2
6.9 months	patients with, weight loss of 2% or more	Median survival from the beginning of Cycle 2

Medical Affairs Professional Society (MAPS) | 2021

Tenet: Beneficence (human benefit)

Unlocking more evidence for better health outcomes

Article Cited By (0) Tweetations (7) Metrics

🗉 Original Paper

Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular Toxicity of Hydroxychloroquine

Matthew Michelson^{1,2}, PhD (b); Tiffany Chow¹, PharmD (b); Neil A Martin³, MD (b); Mike Ross¹, BS (b); Amelia Tee Qiao Ying¹ (b); Steven Minton², PhD (b)

¹Evid Science, El Segundo, CA, United States

²InferLink, El Segundo, CA, United States


³Pacific Neuroscience Institute, Providence St John's Health Center, Santa Monica, CA, United States

Corresponding Author:

Matthew Michelson, PhD Evid Science 2361 Rosencrans Ave Ste 348 El Segundo, CA, 90245-4929 United States Phone: 1 626 765 1903 Email: mmichelson@evidscience.com

ABSTRACT

Background: Rapid access to evidence is crucial in times of an evolving clinical crisis. To that end, we propose a novel approach to answer clinical queries, termed rapid meta-analysis (RMA). Unlike traditional meta-analysis, RMA balances a quick time to production with reasonable data quality assurances, leveraging artificial intelligence (AI) to strike this balance.



headache 48

PROs	First Seen	Used By	Seen in Trial	Associated Instrument(s)
headaches [earliest: 1980] headache severity [earliest: 2011]	1980			QOL QLQ-30 SF-36

Tenet: Nonmaleficence (do not harm)

Provenance and Transparency

- Control
 - Human is in control (AI is "just data")
- Determinism
 - What you get, you get each time (unless you change it!)
- Accuracy
 - Reported in JMIR paper
- Cybersecurity
 - No manipulation of data or algorithms

Tenet: Justice (non discrimination)

- Minimize bias
 - Process all journals and therapy areas we can, not just some
 - Decisions made from a breadth of data (≈75M data points)
 - Rely on English language abstracts (translated)
 - In the future, use Machine Translation to cover any!

Tenet: Dignity

- No gaming
 - Raw machine generated results
 - You can change them, but only you see those changes
 - Implied risk mistakes are not healthcare critical

Result extracted	Recall	Precision	Perfect Precision	F-measure	F-measure (Perfect)
Numerator (N=42)	92.86%	95.12%	95.12%	93.98%	93.98%
Denominator (N=23)	91.30%	91.30%	91.30%	91.30%	91.30%
Percent (N=40)	90.00%	94.74%	92.11%	92.31%	91.04%
Continuous Value (N=29)	89.66%	92.86%	92.86%	91.23%	91.23%
Continuous Unit (N=24)	83.33%	95.24%	90.48%	88.89%	86.76%
Intervention (N=85)	84.71%	94.74%	86.84%	89.44%	85.76%
Outcome (N=100)	95.00%	97.94%	79.38%	96.45%	86.49%

Based on your opinion, where should be strong resonance between medical and AI ethics?

- 1. In everything that healthcare and industry are doing
- 2. It is a must in areas facing patients within healthcare and clinical trials
- 3. Strong resonance is not needed at all; instead it is better to work out actions to mitigate the risks

After hearing the presentation, would you consider the impact of ethics when introducing AI in medical affairs?

- 1. Yes, it makes sense to consider
- 2. Yes, it makes sense but I need still more guidance
- 3. Yes, it make sense but will prefer to wait on others to take the first step
- 4. No, I am not convinced





Rahela Penovski Pharmacist in industry UK Matthew Michelson PhD

President, Genesis Al Genesis Research USA



Sameer Lal SVP Business Development Indegene UK

Thank you! Questions?

Medical Affairs Professional Society (MAPS) | 2021